المؤلفون: Shi Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, People's Republic of China. Electronic address: syuankai@cicams.ac.cn., Li B; Integrated Department, Beijing Chest Hospital, Capital Medical University, Beijing, People's Republic of China., Wu L; Department of Medical Oncology-Chest (2), Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, People's Republic of China., Pan Y; Cancer Chemotherapy Department, Anhui Provincial Hospital, The First Affiliated Hospital of USTC, Hefei, People's Republic of China., Pan Z; Department of Respiratory Diseases, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, People's Republic of China., Liu Y; Department of Medical Oncology, The First Affiliated Hospital of China Medical University, Shenyang, People's Republic of China., Fan Y; Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, People's Republic of China., Ji Y; Medical Oncology Ward 2, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, People's Republic of China., Fang J; Department of Thoracic Oncology II, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/ Beijing), Peking University Cancer Hospital and Institute, Beijing, People's Republic of China., Shi Q; Oncology Department, Fuzhou Pulmonary Hospital of Fujian, Fuzhou, People's Republic of China., Shi J; Department II of Medical Oncology, Linyi Cancer Hospital, Linyi, People's Republic of China., Gao H; Pulmonary Oncology Department, Fifth Medical Center of Chinese PLA General Hospital, Beijing, People's Republic of China., Hu Y; Department of Thoracic Oncology, Hubei Cancer Hospital, The Affiliated Cancer Hospital of Tongji School of Medicine, Huazhong University of Science and Technology, Wuhan, People's Republic of China., Wang X; Department of Medical Oncology, Xuzhou Central Hospital, Xuzhou, People's Republic of China., He Z; Department of Thoracic Oncology, Fujian Cancer Hospital, The Affiliated Cancer Hospital of Fujian Medical University, Fuzhou, People's Republic of China., Ma R; Department II of Chest Physicians, Liaoning Cancer Hospital & Institute, Shenyang, People's Republic of China., Zhang Y; Department I of Respiratory Medicine, Nanjing Chest Hospital, Medical School of Southeast University, Nanjing, People's Republic of China., Jiang D; Medical of Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China., Bai Y; Oncology Hematology Department, China-Japan Union Hospital of Jilin University, Changchun, People's Republic of China., Zhang Y; Thoracic Surgery Department, Xuanwu Hospital, Capital Medical University, Beijing, People's Republic of China., Huang L; Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Bengbu Medical College, Bengbu, People's Republic of China., Zhou T; Oncology Department, Changzhou Tumor Hospital, Changzhou, People's Republic of China., Liu H; Department of Thoracic Medical Oncology, First People's Hospital of Chenzhou City, Chenzhou, People's Republic of China., Wang D; Department of Medical Oncology, Harrison International Peace Hospital, Hengshui, People's Republic of China., Wen Q; Oncology Department, The Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China., Chen G; Department of Medical Oncology, Tumor Hospital of Harbin Medical University, Harbin, People's Republic of China., Zang A; Medicine Oncology, Affiliated Hospital of Hebei University, Baoding, People's Republic of China., Wang X; Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan, People's Republic of China., Zhang X; Department of Respiratory and Critical Care Medicine, The First Hospital of Shanxi Medical University, Taiyuan, People's Republic of China., Hu J; Oncology Department, Yueyang Central hospital, Yueyang, People's Republic of China., Yang R; Internal Second Department, Yunnan Cancer hospital, Kunming, People's Republic of China., Zhang G; Department 1 of Pulmonary & Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China., Gu K; Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China., Wang L; Department of Medical Oncology, Hainan General Hospital, Haikou, People's Republic of China., Wang Q; Department of Medical Oncology, Henan Cancer Hospital, Zhengzhou, People's Republic of China., Wei Z; Pulmonary and Critical Care Medicine Department, The People's Hospital of Nanchuan, Chongqing, People's Republic of China., Li Z; Department of Oncology, 3201 Hospital, Hanzhong, People's Republic of China., Lu H; Department of Oncology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China., Zhang H; Department of Oncology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, People's Republic of China., Chen H; Jiangsu Aosaikang Pharmaceutical Co. Ltd., Nanjing, People's Republic of China., Song T; Jiangsu Aosaikang Pharmaceutical Co. Ltd., Nanjing, People's Republic of China.

المصدر: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2022 Oct; Vol. 17 (10), pp. 1205-1215. Date of Electronic Publication: 2022 Jun 02.

نوع المنشور: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 101274235 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1556-1380 (Electronic) Linking ISSN: 15560864 NLM ISO Abbreviation: J Thorac Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents*/adverse effects , Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/genetics , Carcinoma, Non-Small-Cell Lung*/pathology , Exanthema* , Lung Neoplasms*/drug therapy , Lung Neoplasms*/genetics , Lung Neoplasms*/pathology, Acrylamides ; Aniline Compounds/therapeutic use ; Diarrhea/chemically induced ; ErbB Receptors ; Humans ; Mutation ; Protein Kinase Inhibitors/adverse effects